Fig. 3: Siglec-8 mAb treatment decreases MC activity in acute BLM-mediated lung injury. | Mucosal Immunology

Fig. 3: Siglec-8 mAb treatment decreases MC activity in acute BLM-mediated lung injury.

From: A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation

Fig. 3

a Flow cytometry gating strategy to identify MCs in lungs from Siglec-8 tg mice stained with an anti-Siglec-8 mAb (blue) or FMO (gray). b Absolute MCs and c CD63+ MCs per lung determined by flow cytometry in sham (black), ISO + acute BLM (gray), or anti-S8 + acute BLM (blue) treated mice. d, e Levels of MCPT1 and MCPT4 from overnight ex vivo lung culture in sham (black), ISO + acute BLM (gray), or anti-S8 + acute BLM (blue) treated mice. Data are plotted as mean ± SEM (six mice/group). **P < 0.01; ***P < 0.001 by one-way ANOVA with Tukey’s multiple-comparisons test. BLM bleomycin, FMO fluorescence minus one, ISO isotype control, MCPT mast cell protease.

Back to article page